Copyright © 2015, Evaluate Ltd, All rights reserved.
PD-1s make way for next wave of blockbusters
Based on EvaluatePharma Intelligence

EP Vantage Report



This analysis from EP Vantage offers a round-up of the most valuable R&D assets, based on EvaluatePharma consensus forecasts.

After the recent approvals of Merck & Co's Keytruda and Bristol-Myers Squibb's Opdivo, attention has shifted to what might now represent the industry's most-valuable development stage assets.


Download the article to read more about:

  • Most valuable phase III assets

  • Most valuable assets awaiting regulatory approval

  • Major oncology assets

  • Pipeline value (NPV) by therapy area

To download this article, please confirm your details on the form opposite.